Share-based Payment Arrangement, Expense of Eton Pharmaceuticals, Inc. from 31 Mar 2018 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Eton Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2018 to 31 Mar 2025.
  • Eton Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2025 was $1,200,000, a 46% increase year-over-year.
  • Eton Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $3,165,000, a 0.89% increase from 2023.
  • Eton Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3,137,000, a 26% decline from 2022.
  • Eton Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $4,218,000, a 25% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Eton Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $1,200,000 +$379,000 +46% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q3 2024 $2,383,000 -$4,000 -0.17% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2024 2024 Q3
Q1 2024 $3,086,000 $821,000 -$51,000 -5.8% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $3,137,000 $907,000 -$1,793,000 -202% 01 Oct 2023 31 Dec 2023 10-K 18 Mar 2025 2024 FY
Q3 2023 $4,930,000 $2,387,000 +$1,438,000 +152% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $3,492,000 $785,000 -$515,000 -40% 01 Apr 2023 30 Jun 2023 10-Q 10 Aug 2023 2023 Q2
Q1 2023 $4,007,000 $872,000 -$211,000 -19% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $4,218,000 $886,000 01 Oct 2022 31 Dec 2022 10-K 18 Mar 2025 2024 FY
Q3 2022 $949,000 -$60,000 -5.9% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $1,300,000 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $1,083,000 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q3 2021 $1,009,000 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q4 2019 $1,888,000 $501,000 +$282,000 +129% 01 Oct 2019 31 Dec 2019 10-K 05 Mar 2020 2019 FY
Q3 2019 $1,606,000 $537,000 +$372,000 +225% 01 Jul 2019 30 Sep 2019 10-Q 14 Nov 2019 2019 Q3
Q2 2019 $1,234,000 $505,000 +$89,000 +21% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2019 2019 Q2
Q1 2019 $1,145,000 $345,000 -$705,000 -67% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2019 2019 Q1
Q4 2018 $1,850,000 $219,000 01 Oct 2018 31 Dec 2018 10-K 05 Mar 2020 2019 FY
Q3 2018 $165,000 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019 2019 Q3
Q2 2018 $416,000 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $1,050,000 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1

Eton Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $3,165,000 +$28,000 +0.89% 01 Jan 2024 31 Dec 2024 10-K 18 Mar 2025 2024 FY
2023 $3,137,000 -$1,081,000 -26% 01 Jan 2023 31 Dec 2023 10-K 18 Mar 2025 2024 FY
2022 $4,218,000 +$837,000 +25% 01 Jan 2022 31 Dec 2022 10-K 18 Mar 2025 2024 FY
2021 $3,381,000 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2024 2023 FY
2019 $1,888,000 +$38,000 +2.1% 01 Jan 2019 31 Dec 2019 10-K 05 Mar 2020 2019 FY
2018 $1,850,000 01 Jan 2018 31 Dec 2018 10-K 05 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.